Veterinary Medicines

ICTHIOVAC VR/PD, EMULSION FOR INJECTION FOR SEA BASS

Authorised
  • Photobacterium damselae, subsp. Piscicida, strain DI21, Inactivated
  • Vibrio anguillarum, serotype O1, Inactivated
  • Vibrio anguillarum, serotype O2B, Inactivated
  • Vibrio anguillarum, serotype O2A, Inactivated
Download as PDF

Auðkenning lyfsins

Heiti lyfs:
ICTHIOVAC VR/PD, EMULSION FOR INJECTION FOR SEA BASS
ICTHIOVAC VR/PD, ενέσιμο γαλάκτωμα για λαβράκια
Virkt efni:
Dýrategundir:
Íkomuleið:
  • Til notkunar í kviðarhol

Upplýsingar um lyfið

Virkt efni / Styrkur:
  • Aðeins í boði í English
    60.00
    Relative Percentage Survival
    /
    1.00
    Dose
  • Aðeins í boði í English
    75.00
    Relative Percentage Survival
    /
    1.00
    Dose
  • Aðeins í boði í English
    75.00
    Relative Percentage Survival
    /
    1.00
    Dose
  • Aðeins í boði í English
    75.00
    Relative Percentage Survival
    /
    1.00
    Dose
Lyfjaform:
  • Stungulyf, fleyti
Withdrawal period by route of administration:
  • Intraperitoneal use
    • Seabass
      • Fish meat
        0
        degree day
ATC flokkun (dýralyf):
  • QI10X
Lögformleg staða:
Staða markaðsleyfis:
  • Gilt
Authorised in:
Þessar upplýsingar eru ekki tiltækar fyrir þessa vöru.
Áletrun:

Viðbótarupplýsingar

Entitlement type:
  • Markaðsleyfi
Lagagrundvöllur vöruleyfis:
Markaðsleyfishafi:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Framleiðandi sem ber ábyrgð á lokasamþykkt:
  • Laboratorios Hipra S.A.
Ábyrgt yfirvald:
  • National Organization For Medicines
Markaðsleyfisnúmer:
  • 45403/16/16-08-2017/K-0223001
Dagsetning leyfisbreytingar:
Umsjónarland (RMS):
  • Frakkland
Númer verkferlis:
  • FR/V/0314/001
Þátttökulönd (CMS):
  • Króatía
  • Kýpur
  • Grikkland
  • Ítalía
  • Portúgal
  • Spánn
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."